nodes	percent_of_prediction	percent_of_DWPC	metapath
Bosutinib—CSK—systemic scleroderma	0.333	0.685	CbGaD
Bosutinib—PTK2B—Leflunomide—systemic scleroderma	0.197	0.883	CbGbCtD
Bosutinib—BLK—systemic scleroderma	0.153	0.315	CbGaD
Bosutinib—ABCB1—Lisinopril—systemic scleroderma	0.00706	0.0317	CbGbCtD
Bosutinib—ABCB1—Captopril—systemic scleroderma	0.00529	0.0237	CbGbCtD
Bosutinib—ABCB1—Mycophenolate mofetil—systemic scleroderma	0.00416	0.0187	CbGbCtD
Bosutinib—ABCB1—Prednisone—systemic scleroderma	0.00333	0.0149	CbGbCtD
Bosutinib—CYP3A4—Mycophenolate mofetil—systemic scleroderma	0.00249	0.0112	CbGbCtD
Bosutinib—Vandetanib—BLK—systemic scleroderma	0.00207	1	CrCbGaD
Bosutinib—CYP3A4—Prednisone—systemic scleroderma	0.00199	0.00894	CbGbCtD
Bosutinib—ABCB1—Methotrexate—systemic scleroderma	0.00167	0.00749	CbGbCtD
Bosutinib—TLK1—Mycophenolic acid—Mycophenolate mofetil—systemic scleroderma	0.00138	0.451	CbGdCrCtD
Bosutinib—STK25—Mycophenolic acid—Mycophenolate mofetil—systemic scleroderma	0.000575	0.187	CbGdCrCtD
Bosutinib—CASK—Mycophenolic acid—Mycophenolate mofetil—systemic scleroderma	0.000512	0.167	CbGdCrCtD
Bosutinib—TYRO3—skin of body—systemic scleroderma	0.000349	0.00447	CbGeAlD
Bosutinib—TLK1—lung—systemic scleroderma	0.000348	0.00446	CbGeAlD
Bosutinib—STK26—digestive system—systemic scleroderma	0.000348	0.00445	CbGeAlD
Bosutinib—BMPR2—connective tissue—systemic scleroderma	0.000347	0.00444	CbGeAlD
Bosutinib—VRK2—tendon—systemic scleroderma	0.000344	0.0044	CbGeAlD
Bosutinib—FES—tendon—systemic scleroderma	0.000344	0.0044	CbGeAlD
Bosutinib—PRKCQ—lung—systemic scleroderma	0.000343	0.00439	CbGeAlD
Bosutinib—STK33—lung—systemic scleroderma	0.000338	0.00434	CbGeAlD
Bosutinib—TNIK—tendon—systemic scleroderma	0.000337	0.00432	CbGeAlD
Bosutinib—SYK—tendon—systemic scleroderma	0.000337	0.00432	CbGeAlD
Bosutinib—CDK2—tendon—systemic scleroderma	0.000334	0.00428	CbGeAlD
Bosutinib—MAP4K4—connective tissue—systemic scleroderma	0.000334	0.00427	CbGeAlD
Bosutinib—WEE1—digestive system—systemic scleroderma	0.000333	0.00427	CbGeAlD
Bosutinib—DMPK—digestive system—systemic scleroderma	0.000333	0.00427	CbGeAlD
Bosutinib—PDGFRB—blood vessel—systemic scleroderma	0.000331	0.00425	CbGeAlD
Bosutinib—STK26—tendon—systemic scleroderma	0.000331	0.00424	CbGeAlD
Bosutinib—ROCK1—smooth muscle tissue—systemic scleroderma	0.000326	0.00418	CbGeAlD
Bosutinib—MAP2K1—connective tissue—systemic scleroderma	0.000322	0.00413	CbGeAlD
Bosutinib—CLK3—lung—systemic scleroderma	0.000322	0.00412	CbGeAlD
Bosutinib—DSTYK—lung—systemic scleroderma	0.000322	0.00412	CbGeAlD
Bosutinib—BMX—lung—systemic scleroderma	0.000322	0.00412	CbGeAlD
Bosutinib—CSK—connective tissue—systemic scleroderma	0.00032	0.0041	CbGeAlD
Bosutinib—CHEK2—tendon—systemic scleroderma	0.00032	0.00409	CbGeAlD
Bosutinib—STK25—digestive system—systemic scleroderma	0.000318	0.00407	CbGeAlD
Bosutinib—BMPR2—smooth muscle tissue—systemic scleroderma	0.000317	0.00406	CbGeAlD
Bosutinib—WEE1—tendon—systemic scleroderma	0.000317	0.00406	CbGeAlD
Bosutinib—DMPK—tendon—systemic scleroderma	0.000317	0.00406	CbGeAlD
Bosutinib—CLK1—connective tissue—systemic scleroderma	0.000316	0.00405	CbGeAlD
Bosutinib—CASK—lung—systemic scleroderma	0.000315	0.00403	CbGeAlD
Bosutinib—BMPR2—skin of body—systemic scleroderma	0.000313	0.00401	CbGeAlD
Bosutinib—EIF2AK1—lung—systemic scleroderma	0.000311	0.00399	CbGeAlD
Bosutinib—BMP2K—connective tissue—systemic scleroderma	0.00031	0.00397	CbGeAlD
Bosutinib—PLK2—digestive system—systemic scleroderma	0.000309	0.00396	CbGeAlD
Bosutinib—SRMS—lung—systemic scleroderma	0.000308	0.00394	CbGeAlD
Bosutinib—MAP4K4—smooth muscle tissue—systemic scleroderma	0.000305	0.00391	CbGeAlD
Bosutinib—TXK—lung—systemic scleroderma	0.000305	0.0039	CbGeAlD
Bosutinib—CSK—Mycophenolic acid—Mycophenolate mofetil—systemic scleroderma	0.000305	0.0992	CbGdCrCtD
Bosutinib—STK25—tendon—systemic scleroderma	0.000303	0.00388	CbGeAlD
Bosutinib—FES—lung—systemic scleroderma	0.000302	0.00386	CbGeAlD
Bosutinib—VRK2—lung—systemic scleroderma	0.000302	0.00386	CbGeAlD
Bosutinib—PTK2B—connective tissue—systemic scleroderma	0.0003	0.00384	CbGeAlD
Bosutinib—TNIK—lung—systemic scleroderma	0.000296	0.00379	CbGeAlD
Bosutinib—SYK—lung—systemic scleroderma	0.000296	0.00379	CbGeAlD
Bosutinib—STK4—digestive system—systemic scleroderma	0.000296	0.00379	CbGeAlD
Bosutinib—MAP2K1—smooth muscle tissue—systemic scleroderma	0.000295	0.00378	CbGeAlD
Bosutinib—PLK2—tendon—systemic scleroderma	0.000294	0.00377	CbGeAlD
Bosutinib—CDK2—lung—systemic scleroderma	0.000293	0.00375	CbGeAlD
Bosutinib—CSK—smooth muscle tissue—systemic scleroderma	0.000293	0.00375	CbGeAlD
Bosutinib—SIK3—tendon—systemic scleroderma	0.000292	0.00374	CbGeAlD
Bosutinib—MAP2K1—skin of body—systemic scleroderma	0.000291	0.00373	CbGeAlD
Bosutinib—STK35—skin of body—systemic scleroderma	0.000291	0.00373	CbGeAlD
Bosutinib—CSNK1A1—smooth muscle tissue—systemic scleroderma	0.000291	0.00373	CbGeAlD
Bosutinib—STK26—lung—systemic scleroderma	0.00029	0.00372	CbGeAlD
Bosutinib—SIK1—connective tissue—systemic scleroderma	0.00029	0.00372	CbGeAlD
Bosutinib—CSK—skin of body—systemic scleroderma	0.000289	0.0037	CbGeAlD
Bosutinib—CSNK1A1—skin of body—systemic scleroderma	0.000287	0.00368	CbGeAlD
Bosutinib—ERBB3—connective tissue—systemic scleroderma	0.000284	0.00364	CbGeAlD
Bosutinib—MAP3K2—connective tissue—systemic scleroderma	0.000282	0.00361	CbGeAlD
Bosutinib—CHEK2—lung—systemic scleroderma	0.00028	0.00359	CbGeAlD
Bosutinib—ALK—digestive system—systemic scleroderma	0.000279	0.00358	CbGeAlD
Bosutinib—EPHA5—digestive system—systemic scleroderma	0.000279	0.00358	CbGeAlD
Bosutinib—DMPK—lung—systemic scleroderma	0.000278	0.00356	CbGeAlD
Bosutinib—WEE1—lung—systemic scleroderma	0.000278	0.00356	CbGeAlD
Bosutinib—CAMK1D—tendon—systemic scleroderma	0.000278	0.00356	CbGeAlD
Bosutinib—PTK2—connective tissue—systemic scleroderma	0.000276	0.00353	CbGeAlD
Bosutinib—STK24—tendon—systemic scleroderma	0.000275	0.00352	CbGeAlD
Bosutinib—PTK2B—smooth muscle tissue—systemic scleroderma	0.000274	0.00351	CbGeAlD
Bosutinib—CSNK1E—skin of body—systemic scleroderma	0.000266	0.00341	CbGeAlD
Bosutinib—FER—tendon—systemic scleroderma	0.000266	0.00341	CbGeAlD
Bosutinib—STK25—lung—systemic scleroderma	0.000266	0.0034	CbGeAlD
Bosutinib—RPS6KB1—connective tissue—systemic scleroderma	0.000265	0.0034	CbGeAlD
Bosutinib—EPHA3—lung—systemic scleroderma	0.000264	0.00338	CbGeAlD
Bosutinib—AXL—connective tissue—systemic scleroderma	0.000263	0.00337	CbGeAlD
Bosutinib—SIK1—skin of body—systemic scleroderma	0.000262	0.00336	CbGeAlD
Bosutinib—MAP4K1—tendon—systemic scleroderma	0.00026	0.00334	CbGeAlD
Bosutinib—MAP2K2—smooth muscle tissue—systemic scleroderma	0.00026	0.00332	CbGeAlD
Bosutinib—BTK—tendon—systemic scleroderma	0.000259	0.00332	CbGeAlD
Bosutinib—PLK2—lung—systemic scleroderma	0.000258	0.00331	CbGeAlD
Bosutinib—ROCK1—digestive system—systemic scleroderma	0.000258	0.0033	CbGeAlD
Bosutinib—ERBB3—skin of body—systemic scleroderma	0.000257	0.00329	CbGeAlD
Bosutinib—SIK3—lung—systemic scleroderma	0.000256	0.00329	CbGeAlD
Bosutinib—MAP2K2—skin of body—systemic scleroderma	0.000256	0.00328	CbGeAlD
Bosutinib—MAP3K7—smooth muscle tissue—systemic scleroderma	0.000255	0.00327	CbGeAlD
Bosutinib—PTK2—smooth muscle tissue—systemic scleroderma	0.000252	0.00323	CbGeAlD
Bosutinib—MAP4K2—tendon—systemic scleroderma	0.000252	0.00323	CbGeAlD
Bosutinib—EPHB4—connective tissue—systemic scleroderma	0.000251	0.00322	CbGeAlD
Bosutinib—BMPR2—digestive system—systemic scleroderma	0.00025	0.00321	CbGeAlD
Bosutinib—PTK2—skin of body—systemic scleroderma	0.000249	0.00319	CbGeAlD
Bosutinib—ERBB4—tendon—systemic scleroderma	0.000248	0.00318	CbGeAlD
Bosutinib—STK3—tendon—systemic scleroderma	0.000248	0.00318	CbGeAlD
Bosutinib—EPHB3—digestive system—systemic scleroderma	0.000248	0.00318	CbGeAlD
Bosutinib—IRAK1—smooth muscle tissue—systemic scleroderma	0.000247	0.00317	CbGeAlD
Bosutinib—STK4—lung—systemic scleroderma	0.000247	0.00316	CbGeAlD
Bosutinib—FYN—connective tissue—systemic scleroderma	0.000246	0.00315	CbGeAlD
Bosutinib—CAMK1D—lung—systemic scleroderma	0.000244	0.00313	CbGeAlD
Bosutinib—RPS6KB1—smooth muscle tissue—systemic scleroderma	0.000243	0.00311	CbGeAlD
Bosutinib—STK24—lung—systemic scleroderma	0.000241	0.00309	CbGeAlD
Bosutinib—MAP4K4—digestive system—systemic scleroderma	0.000241	0.00309	CbGeAlD
Bosutinib—AXL—smooth muscle tissue—systemic scleroderma	0.00024	0.00308	CbGeAlD
Bosutinib—BMPR2—tendon—systemic scleroderma	0.000238	0.00305	CbGeAlD
Bosutinib—AXL—skin of body—systemic scleroderma	0.000237	0.00304	CbGeAlD
Bosutinib—STK36—tendon—systemic scleroderma	0.000236	0.00303	CbGeAlD
Bosutinib—MERTK—tendon—systemic scleroderma	0.000234	0.00299	CbGeAlD
Bosutinib—FER—lung—systemic scleroderma	0.000233	0.00299	CbGeAlD
Bosutinib—ALK—lung—systemic scleroderma	0.000233	0.00299	CbGeAlD
Bosutinib—MAP2K1—digestive system—systemic scleroderma	0.000233	0.00298	CbGeAlD
Bosutinib—CSK—digestive system—systemic scleroderma	0.000231	0.00296	CbGeAlD
Bosutinib—CSNK1A1—digestive system—systemic scleroderma	0.00023	0.00294	CbGeAlD
Bosutinib—EPHB4—smooth muscle tissue—systemic scleroderma	0.00023	0.00294	CbGeAlD
Bosutinib—MAP4K4—tendon—systemic scleroderma	0.000229	0.00294	CbGeAlD
Bosutinib—MAP3K19—lung—systemic scleroderma	0.000229	0.00293	CbGeAlD
Bosutinib—MAP4K1—lung—systemic scleroderma	0.000229	0.00293	CbGeAlD
Bosutinib—HCK—digestive system—systemic scleroderma	0.000228	0.00292	CbGeAlD
Bosutinib—CLK1—digestive system—systemic scleroderma	0.000228	0.00292	CbGeAlD
Bosutinib—BCR—tendon—systemic scleroderma	0.000228	0.00292	CbGeAlD
Bosutinib—BTK—lung—systemic scleroderma	0.000227	0.00291	CbGeAlD
Bosutinib—MAP3K12—tendon—systemic scleroderma	0.000226	0.0029	CbGeAlD
Bosutinib—FYN—smooth muscle tissue—systemic scleroderma	0.000225	0.00288	CbGeAlD
Bosutinib—TNK2—lung—systemic scleroderma	0.000224	0.00287	CbGeAlD
Bosutinib—CAMK2G—digestive system—systemic scleroderma	0.000224	0.00287	CbGeAlD
Bosutinib—FYN—skin of body—systemic scleroderma	0.000222	0.00284	CbGeAlD
Bosutinib—YES1—connective tissue—systemic scleroderma	0.000222	0.00284	CbGeAlD
Bosutinib—STK35—tendon—systemic scleroderma	0.000221	0.00284	CbGeAlD
Bosutinib—MAP4K2—lung—systemic scleroderma	0.000221	0.00283	CbGeAlD
Bosutinib—CSK—tendon—systemic scleroderma	0.00022	0.00282	CbGeAlD
Bosutinib—MAP4K5—smooth muscle tissue—systemic scleroderma	0.00022	0.00282	CbGeAlD
Bosutinib—TAOK3—connective tissue—systemic scleroderma	0.000219	0.00281	CbGeAlD
Bosutinib—CSNK1A1—tendon—systemic scleroderma	0.000219	0.0028	CbGeAlD
Bosutinib—ERBB4—lung—systemic scleroderma	0.000218	0.00279	CbGeAlD
Bosutinib—STK3—lung—systemic scleroderma	0.000218	0.00279	CbGeAlD
Bosutinib—HCK—tendon—systemic scleroderma	0.000217	0.00278	CbGeAlD
Bosutinib—CLK1—tendon—systemic scleroderma	0.000217	0.00278	CbGeAlD
Bosutinib—MAP3K3—skin of body—systemic scleroderma	0.000217	0.00278	CbGeAlD
Bosutinib—PTK2B—digestive system—systemic scleroderma	0.000216	0.00277	CbGeAlD
Bosutinib—ABL2—tendon—systemic scleroderma	0.000216	0.00277	CbGeAlD
Bosutinib—ROCK1—lung—systemic scleroderma	0.000215	0.00276	CbGeAlD
Bosutinib—SRC—connective tissue—systemic scleroderma	0.000213	0.00273	CbGeAlD
Bosutinib—BMP2K—tendon—systemic scleroderma	0.000213	0.00273	CbGeAlD
Bosutinib—CAMK2G—tendon—systemic scleroderma	0.000213	0.00273	CbGeAlD
Bosutinib—CSNK1E—digestive system—systemic scleroderma	0.000213	0.00273	CbGeAlD
Bosutinib—LRRK2—tendon—systemic scleroderma	0.000211	0.00271	CbGeAlD
Bosutinib—BMPR2—lung—systemic scleroderma	0.000209	0.00268	CbGeAlD
Bosutinib—STK36—lung—systemic scleroderma	0.000207	0.00266	CbGeAlD
Bosutinib—EPHB3—lung—systemic scleroderma	0.000207	0.00266	CbGeAlD
Bosutinib—PTK2B—tendon—systemic scleroderma	0.000206	0.00264	CbGeAlD
Bosutinib—ERBB3—digestive system—systemic scleroderma	0.000205	0.00263	CbGeAlD
Bosutinib—MERTK—lung—systemic scleroderma	0.000205	0.00263	CbGeAlD
Bosutinib—ULK3—digestive system—systemic scleroderma	0.000205	0.00262	CbGeAlD
Bosutinib—MAP2K2—digestive system—systemic scleroderma	0.000205	0.00262	CbGeAlD
Bosutinib—YES1—smooth muscle tissue—systemic scleroderma	0.000203	0.0026	CbGeAlD
Bosutinib—CSNK1E—tendon—systemic scleroderma	0.000203	0.0026	CbGeAlD
Bosutinib—MAP4K4—lung—systemic scleroderma	0.000201	0.00258	CbGeAlD
Bosutinib—BCR—lung—systemic scleroderma	0.0002	0.00256	CbGeAlD
Bosutinib—NUAK2—lung—systemic scleroderma	0.0002	0.00256	CbGeAlD
Bosutinib—SIK1—tendon—systemic scleroderma	0.000199	0.00255	CbGeAlD
Bosutinib—IRAK4—tendon—systemic scleroderma	0.000199	0.00255	CbGeAlD
Bosutinib—PTK2—digestive system—systemic scleroderma	0.000199	0.00255	CbGeAlD
Bosutinib—TBK1—digestive system—systemic scleroderma	0.000199	0.00255	CbGeAlD
Bosutinib—MAP3K12—lung—systemic scleroderma	0.000198	0.00254	CbGeAlD
Bosutinib—EPHA4—tendon—systemic scleroderma	0.000197	0.00253	CbGeAlD
Bosutinib—SRC—smooth muscle tissue—systemic scleroderma	0.000195	0.0025	CbGeAlD
Bosutinib—MAP2K2—tendon—systemic scleroderma	0.000195	0.0025	CbGeAlD
Bosutinib—ULK3—tendon—systemic scleroderma	0.000195	0.0025	CbGeAlD
Bosutinib—MAP2K1—lung—systemic scleroderma	0.000194	0.00249	CbGeAlD
Bosutinib—STK35—lung—systemic scleroderma	0.000194	0.00249	CbGeAlD
Bosutinib—CSK—lung—systemic scleroderma	0.000193	0.00247	CbGeAlD
Bosutinib—SRC—skin of body—systemic scleroderma	0.000193	0.00247	CbGeAlD
Bosutinib—CSNK1A1—lung—systemic scleroderma	0.000192	0.00246	CbGeAlD
Bosutinib—MAP3K7—tendon—systemic scleroderma	0.000192	0.00246	CbGeAlD
Bosutinib—RPS6KB1—digestive system—systemic scleroderma	0.000192	0.00246	CbGeAlD
Bosutinib—CSF1R—connective tissue—systemic scleroderma	0.000192	0.00245	CbGeAlD
Bosutinib—HCK—lung—systemic scleroderma	0.000191	0.00244	CbGeAlD
Bosutinib—CLK1—lung—systemic scleroderma	0.000191	0.00244	CbGeAlD
Bosutinib—FGR—digestive system—systemic scleroderma	0.00019	0.00244	CbGeAlD
Bosutinib—TBK1—tendon—systemic scleroderma	0.00019	0.00243	CbGeAlD
Bosutinib—PTK2—tendon—systemic scleroderma	0.00019	0.00243	CbGeAlD
Bosutinib—ABL2—lung—systemic scleroderma	0.000189	0.00243	CbGeAlD
Bosutinib—CAMK2G—lung—systemic scleroderma	0.000187	0.0024	CbGeAlD
Bosutinib—BMP2K—lung—systemic scleroderma	0.000187	0.0024	CbGeAlD
Bosutinib—IRAK1—tendon—systemic scleroderma	0.000186	0.00238	CbGeAlD
Bosutinib—LRRK2—lung—systemic scleroderma	0.000185	0.00238	CbGeAlD
Bosutinib—EGFR—lung—systemic scleroderma	0.000185	0.00237	CbGeAlD
Bosutinib—RPS6KB1—tendon—systemic scleroderma	0.000182	0.00234	CbGeAlD
Bosutinib—EPHB4—digestive system—systemic scleroderma	0.000181	0.00232	CbGeAlD
Bosutinib—FGR—tendon—systemic scleroderma	0.000181	0.00232	CbGeAlD
Bosutinib—PTK2B—lung—systemic scleroderma	0.000181	0.00231	CbGeAlD
Bosutinib—AXL—tendon—systemic scleroderma	0.000181	0.00231	CbGeAlD
Bosutinib—EPHA2—digestive system—systemic scleroderma	0.000178	0.00228	CbGeAlD
Bosutinib—CSNK1E—lung—systemic scleroderma	0.000178	0.00228	CbGeAlD
Bosutinib—FYN—digestive system—systemic scleroderma	0.000178	0.00227	CbGeAlD
Bosutinib—CSF1R—smooth muscle tissue—systemic scleroderma	0.000175	0.00225	CbGeAlD
Bosutinib—SIK1—lung—systemic scleroderma	0.000175	0.00224	CbGeAlD
Bosutinib—IRAK4—lung—systemic scleroderma	0.000175	0.00224	CbGeAlD
Bosutinib—SLK—tendon—systemic scleroderma	0.000174	0.00223	CbGeAlD
Bosutinib—EPHA4—lung—systemic scleroderma	0.000173	0.00222	CbGeAlD
Bosutinib—CSF1R—skin of body—systemic scleroderma	0.000173	0.00222	CbGeAlD
Bosutinib—EPHB4—tendon—systemic scleroderma	0.000173	0.00221	CbGeAlD
Bosutinib—ERBB3—lung—systemic scleroderma	0.000172	0.0022	CbGeAlD
Bosutinib—ULK3—lung—systemic scleroderma	0.000171	0.00219	CbGeAlD
Bosutinib—MAP2K2—lung—systemic scleroderma	0.000171	0.00219	CbGeAlD
Bosutinib—PDGFRB—connective tissue—systemic scleroderma	0.00017	0.00218	CbGeAlD
Bosutinib—MAP3K2—lung—systemic scleroderma	0.00017	0.00218	CbGeAlD
Bosutinib—EPHA2—tendon—systemic scleroderma	0.000169	0.00217	CbGeAlD
Bosutinib—FYN—tendon—systemic scleroderma	0.000169	0.00216	CbGeAlD
Bosutinib—MAP3K7—lung—systemic scleroderma	0.000168	0.00216	CbGeAlD
Bosutinib—TBK1—lung—systemic scleroderma	0.000166	0.00213	CbGeAlD
Bosutinib—PTK2—lung—systemic scleroderma	0.000166	0.00213	CbGeAlD
Bosutinib—MAP3K3—tendon—systemic scleroderma	0.000165	0.00212	CbGeAlD
Bosutinib—MAP4K5—tendon—systemic scleroderma	0.000165	0.00212	CbGeAlD
Bosutinib—IRAK1—lung—systemic scleroderma	0.000163	0.00209	CbGeAlD
Bosutinib—YES1—digestive system—systemic scleroderma	0.00016	0.00205	CbGeAlD
Bosutinib—RPS6KB1—lung—systemic scleroderma	0.00016	0.00205	CbGeAlD
Bosutinib—FGR—lung—systemic scleroderma	0.000159	0.00204	CbGeAlD
Bosutinib—LCK—lung—systemic scleroderma	0.000159	0.00204	CbGeAlD
Bosutinib—STK10—digestive system—systemic scleroderma	0.000159	0.00203	CbGeAlD
Bosutinib—AXL—lung—systemic scleroderma	0.000158	0.00203	CbGeAlD
Bosutinib—TAOK3—digestive system—systemic scleroderma	0.000158	0.00203	CbGeAlD
Bosutinib—PDGFRB—smooth muscle tissue—systemic scleroderma	0.000155	0.00199	CbGeAlD
Bosutinib—SRC—digestive system—systemic scleroderma	0.000154	0.00198	CbGeAlD
Bosutinib—PDGFRB—skin of body—systemic scleroderma	0.000153	0.00197	CbGeAlD
Bosutinib—SLK—lung—systemic scleroderma	0.000153	0.00195	CbGeAlD
Bosutinib—YES1—tendon—systemic scleroderma	0.000153	0.00195	CbGeAlD
Bosutinib—ABL1—connective tissue—systemic scleroderma	0.000151	0.00194	CbGeAlD
Bosutinib—EPHB4—lung—systemic scleroderma	0.000151	0.00194	CbGeAlD
Bosutinib—STK10—tendon—systemic scleroderma	0.000151	0.00194	CbGeAlD
Bosutinib—TAOK3—tendon—systemic scleroderma	0.000151	0.00193	CbGeAlD
Bosutinib—EPHA2—lung—systemic scleroderma	0.000149	0.0019	CbGeAlD
Bosutinib—FYN—lung—systemic scleroderma	0.000148	0.0019	CbGeAlD
Bosutinib—MAP3K3—lung—systemic scleroderma	0.000145	0.00186	CbGeAlD
Bosutinib—MAP4K5—lung—systemic scleroderma	0.000145	0.00186	CbGeAlD
Bosutinib—ABL1—smooth muscle tissue—systemic scleroderma	0.000139	0.00178	CbGeAlD
Bosutinib—CSF1R—digestive system—systemic scleroderma	0.000138	0.00177	CbGeAlD
Bosutinib—ABL1—skin of body—systemic scleroderma	0.000137	0.00175	CbGeAlD
Bosutinib—MAP2K5—tendon—systemic scleroderma	0.000135	0.00173	CbGeAlD
Bosutinib—YES1—lung—systemic scleroderma	0.000134	0.00171	CbGeAlD
Bosutinib—STK10—lung—systemic scleroderma	0.000133	0.0017	CbGeAlD
Bosutinib—TAOK3—lung—systemic scleroderma	0.000132	0.00169	CbGeAlD
Bosutinib—CSF1R—tendon—systemic scleroderma	0.000132	0.00169	CbGeAlD
Bosutinib—SRC—lung—systemic scleroderma	0.000129	0.00165	CbGeAlD
Bosutinib—PDGFRB—digestive system—systemic scleroderma	0.000123	0.00157	CbGeAlD
Bosutinib—Gastrointestinal pain—Captopril—systemic scleroderma	0.000121	0.00137	CcSEcCtD
Bosutinib—Asthenia—Mometasone—systemic scleroderma	0.000121	0.00137	CcSEcCtD
Bosutinib—Unspecified disorder of skin and subcutaneous tissue—Mycophenolic acid—systemic scleroderma	0.00012	0.00137	CcSEcCtD
Bosutinib—Tinnitus—Mycophenolate mofetil—systemic scleroderma	0.00012	0.00137	CcSEcCtD
Bosutinib—Cardiac disorder—Mycophenolate mofetil—systemic scleroderma	0.00012	0.00136	CcSEcCtD
Bosutinib—Discomfort—Mycophenolic acid—systemic scleroderma	0.00012	0.00136	CcSEcCtD
Bosutinib—Nervous system disorder—Leflunomide—systemic scleroderma	0.000119	0.00136	CcSEcCtD
Bosutinib—Thrombocytopenia—Leflunomide—systemic scleroderma	0.000119	0.00135	CcSEcCtD
Bosutinib—Pruritus—Mometasone—systemic scleroderma	0.000119	0.00135	CcSEcCtD
Bosutinib—Ill-defined disorder—Lisinopril—systemic scleroderma	0.000119	0.00135	CcSEcCtD
Bosutinib—MAP2K5—lung—systemic scleroderma	0.000118	0.00152	CbGeAlD
Bosutinib—Anaemia—Lisinopril—systemic scleroderma	0.000118	0.00135	CcSEcCtD
Bosutinib—Skin disorder—Leflunomide—systemic scleroderma	0.000118	0.00134	CcSEcCtD
Bosutinib—Musculoskeletal discomfort—Azathioprine—systemic scleroderma	0.000117	0.00133	CcSEcCtD
Bosutinib—PDGFRB—tendon—systemic scleroderma	0.000117	0.0015	CbGeAlD
Bosutinib—Abdominal pain—Captopril—systemic scleroderma	0.000117	0.00133	CcSEcCtD
Bosutinib—Body temperature increased—Captopril—systemic scleroderma	0.000117	0.00133	CcSEcCtD
Bosutinib—Mediastinal disorder—Mycophenolate mofetil—systemic scleroderma	0.000116	0.00132	CcSEcCtD
Bosutinib—Oedema—Mycophenolic acid—systemic scleroderma	0.000116	0.00132	CcSEcCtD
Bosutinib—Nausea—Pentoxifylline—systemic scleroderma	0.000116	0.00132	CcSEcCtD
Bosutinib—CSF1R—lung—systemic scleroderma	0.000116	0.00148	CbGeAlD
Bosutinib—Malaise—Lisinopril—systemic scleroderma	0.000116	0.00131	CcSEcCtD
Bosutinib—Infection—Mycophenolic acid—systemic scleroderma	0.000115	0.00131	CcSEcCtD
Bosutinib—Diarrhoea—Mometasone—systemic scleroderma	0.000115	0.00131	CcSEcCtD
Bosutinib—Leukopenia—Lisinopril—systemic scleroderma	0.000115	0.0013	CcSEcCtD
Bosutinib—Renal failure acute—Methotrexate—systemic scleroderma	0.000114	0.0013	CcSEcCtD
Bosutinib—Nervous system disorder—Mycophenolic acid—systemic scleroderma	0.000114	0.00129	CcSEcCtD
Bosutinib—Thrombocytopenia—Mycophenolic acid—systemic scleroderma	0.000114	0.00129	CcSEcCtD
Bosutinib—Skin disorder—Mycophenolic acid—systemic scleroderma	0.000113	0.00128	CcSEcCtD
Bosutinib—Malnutrition—Mycophenolate mofetil—systemic scleroderma	0.000112	0.00128	CcSEcCtD
Bosutinib—Cough—Lisinopril—systemic scleroderma	0.000112	0.00127	CcSEcCtD
Bosutinib—Alanine aminotransferase increased—Prednisone—systemic scleroderma	0.000111	0.00127	CcSEcCtD
Bosutinib—Gastrointestinal disorder—Azathioprine—systemic scleroderma	0.000111	0.00126	CcSEcCtD
Bosutinib—Musculoskeletal discomfort—Leflunomide—systemic scleroderma	0.000111	0.00126	CcSEcCtD
Bosutinib—Dysgeusia—Mycophenolate mofetil—systemic scleroderma	0.00011	0.00125	CcSEcCtD
Bosutinib—ABL1—digestive system—systemic scleroderma	0.000109	0.0014	CbGeAlD
Bosutinib—Chest pain—Lisinopril—systemic scleroderma	0.000109	0.00124	CcSEcCtD
Bosutinib—Myalgia—Lisinopril—systemic scleroderma	0.000109	0.00124	CcSEcCtD
Bosutinib—Arthralgia—Lisinopril—systemic scleroderma	0.000109	0.00124	CcSEcCtD
Bosutinib—Back pain—Mycophenolate mofetil—systemic scleroderma	0.000109	0.00123	CcSEcCtD
Bosutinib—Dyspnoea—Leflunomide—systemic scleroderma	0.000108	0.00123	CcSEcCtD
Bosutinib—Unspecified disorder of skin and subcutaneous tissue—Lisinopril—systemic scleroderma	0.000108	0.00123	CcSEcCtD
Bosutinib—Discomfort—Lisinopril—systemic scleroderma	0.000108	0.00122	CcSEcCtD
Bosutinib—Vomiting—Mometasone—systemic scleroderma	0.000107	0.00121	CcSEcCtD
Bosutinib—Feeling abnormal—Azathioprine—systemic scleroderma	0.000106	0.00121	CcSEcCtD
Bosutinib—Rash—Mometasone—systemic scleroderma	0.000106	0.0012	CcSEcCtD
Bosutinib—Asthenia—Captopril—systemic scleroderma	0.000106	0.0012	CcSEcCtD
Bosutinib—Dermatitis—Mometasone—systemic scleroderma	0.000106	0.0012	CcSEcCtD
Bosutinib—Decreased appetite—Leflunomide—systemic scleroderma	0.000106	0.0012	CcSEcCtD
Bosutinib—Musculoskeletal discomfort—Mycophenolic acid—systemic scleroderma	0.000106	0.0012	CcSEcCtD
Bosutinib—Gastrointestinal pain—Azathioprine—systemic scleroderma	0.000105	0.0012	CcSEcCtD
Bosutinib—Headache—Mometasone—systemic scleroderma	0.000105	0.0012	CcSEcCtD
Bosutinib—Gastrointestinal disorder—Leflunomide—systemic scleroderma	0.000105	0.00119	CcSEcCtD
Bosutinib—Fatigue—Leflunomide—systemic scleroderma	0.000105	0.00119	CcSEcCtD
Bosutinib—Anaphylactic shock—Lisinopril—systemic scleroderma	0.000105	0.00119	CcSEcCtD
Bosutinib—Oedema—Lisinopril—systemic scleroderma	0.000105	0.00119	CcSEcCtD
Bosutinib—Pruritus—Captopril—systemic scleroderma	0.000104	0.00119	CcSEcCtD
Bosutinib—Ill-defined disorder—Mycophenolate mofetil—systemic scleroderma	0.000104	0.00118	CcSEcCtD
Bosutinib—ABL1—tendon—systemic scleroderma	0.000104	0.00133	CbGeAlD
Bosutinib—Pain—Leflunomide—systemic scleroderma	0.000104	0.00118	CcSEcCtD
Bosutinib—Infection—Lisinopril—systemic scleroderma	0.000104	0.00118	CcSEcCtD
Bosutinib—Anaemia—Mycophenolate mofetil—systemic scleroderma	0.000104	0.00118	CcSEcCtD
Bosutinib—Dyspnoea—Mycophenolic acid—systemic scleroderma	0.000103	0.00118	CcSEcCtD
Bosutinib—PDGFRB—lung—systemic scleroderma	0.000103	0.00131	CbGeAlD
Bosutinib—Thrombocytopenia—Lisinopril—systemic scleroderma	0.000102	0.00116	CcSEcCtD
Bosutinib—Neutropenia—Prednisone—systemic scleroderma	0.000102	0.00116	CcSEcCtD
Bosutinib—Body temperature increased—Azathioprine—systemic scleroderma	0.000102	0.00116	CcSEcCtD
Bosutinib—Abdominal pain—Azathioprine—systemic scleroderma	0.000102	0.00116	CcSEcCtD
Bosutinib—Skin disorder—Lisinopril—systemic scleroderma	0.000102	0.00115	CcSEcCtD
Bosutinib—Malaise—Mycophenolate mofetil—systemic scleroderma	0.000101	0.00115	CcSEcCtD
Bosutinib—Diarrhoea—Captopril—systemic scleroderma	0.000101	0.00115	CcSEcCtD
Bosutinib—Decreased appetite—Mycophenolic acid—systemic scleroderma	0.000101	0.00115	CcSEcCtD
Bosutinib—Leukopenia—Mycophenolate mofetil—systemic scleroderma	0.0001	0.00114	CcSEcCtD
Bosutinib—Feeling abnormal—Leflunomide—systemic scleroderma	0.0001	0.00114	CcSEcCtD
Bosutinib—Gastrointestinal disorder—Mycophenolic acid—systemic scleroderma	0.0001	0.00114	CcSEcCtD
Bosutinib—Fatigue—Mycophenolic acid—systemic scleroderma	0.0001	0.00114	CcSEcCtD
Bosutinib—Nausea—Mometasone—systemic scleroderma	9.98e-05	0.00113	CcSEcCtD
Bosutinib—Gastrointestinal pain—Leflunomide—systemic scleroderma	9.95e-05	0.00113	CcSEcCtD
Bosutinib—Pain—Mycophenolic acid—systemic scleroderma	9.93e-05	0.00113	CcSEcCtD
Bosutinib—Cough—Mycophenolate mofetil—systemic scleroderma	9.79e-05	0.00111	CcSEcCtD
Bosutinib—Dizziness—Captopril—systemic scleroderma	9.76e-05	0.00111	CcSEcCtD
Bosutinib—Urticaria—Leflunomide—systemic scleroderma	9.67e-05	0.0011	CcSEcCtD
Bosutinib—Body temperature increased—Leflunomide—systemic scleroderma	9.62e-05	0.00109	CcSEcCtD
Bosutinib—Abdominal pain—Leflunomide—systemic scleroderma	9.62e-05	0.00109	CcSEcCtD
Bosutinib—Feeling abnormal—Mycophenolic acid—systemic scleroderma	9.56e-05	0.00109	CcSEcCtD
Bosutinib—Chest pain—Mycophenolate mofetil—systemic scleroderma	9.55e-05	0.00109	CcSEcCtD
Bosutinib—Arthralgia—Mycophenolate mofetil—systemic scleroderma	9.55e-05	0.00109	CcSEcCtD
Bosutinib—Myalgia—Mycophenolate mofetil—systemic scleroderma	9.55e-05	0.00109	CcSEcCtD
Bosutinib—Musculoskeletal discomfort—Lisinopril—systemic scleroderma	9.52e-05	0.00108	CcSEcCtD
Bosutinib—Gastrointestinal pain—Mycophenolic acid—systemic scleroderma	9.49e-05	0.00108	CcSEcCtD
Bosutinib—Unspecified disorder of skin and subcutaneous tissue—Mycophenolate mofetil—systemic scleroderma	9.49e-05	0.00108	CcSEcCtD
Bosutinib—Discomfort—Mycophenolate mofetil—systemic scleroderma	9.44e-05	0.00107	CcSEcCtD
Bosutinib—Vomiting—Captopril—systemic scleroderma	9.39e-05	0.00107	CcSEcCtD
Bosutinib—Dyspnoea—Lisinopril—systemic scleroderma	9.32e-05	0.00106	CcSEcCtD
Bosutinib—Rash—Captopril—systemic scleroderma	9.31e-05	0.00106	CcSEcCtD
Bosutinib—Dermatitis—Captopril—systemic scleroderma	9.3e-05	0.00106	CcSEcCtD
Bosutinib—Headache—Captopril—systemic scleroderma	9.25e-05	0.00105	CcSEcCtD
Bosutinib—ABCB1—blood vessel—systemic scleroderma	9.19e-05	0.00118	CbGeAlD
Bosutinib—Abdominal pain—Mycophenolic acid—systemic scleroderma	9.18e-05	0.00104	CcSEcCtD
Bosutinib—Body temperature increased—Mycophenolic acid—systemic scleroderma	9.18e-05	0.00104	CcSEcCtD
Bosutinib—Anaphylactic shock—Mycophenolate mofetil—systemic scleroderma	9.16e-05	0.00104	CcSEcCtD
Bosutinib—Oedema—Mycophenolate mofetil—systemic scleroderma	9.16e-05	0.00104	CcSEcCtD
Bosutinib—ABL1—lung—systemic scleroderma	9.14e-05	0.00117	CbGeAlD
Bosutinib—Infection—Mycophenolate mofetil—systemic scleroderma	9.1e-05	0.00103	CcSEcCtD
Bosutinib—Decreased appetite—Lisinopril—systemic scleroderma	9.09e-05	0.00103	CcSEcCtD
Bosutinib—Gastrointestinal disorder—Lisinopril—systemic scleroderma	9.03e-05	0.00103	CcSEcCtD
Bosutinib—Fatigue—Lisinopril—systemic scleroderma	9.01e-05	0.00102	CcSEcCtD
Bosutinib—Nervous system disorder—Mycophenolate mofetil—systemic scleroderma	8.98e-05	0.00102	CcSEcCtD
Bosutinib—Thrombocytopenia—Mycophenolate mofetil—systemic scleroderma	8.97e-05	0.00102	CcSEcCtD
Bosutinib—Pain—Lisinopril—systemic scleroderma	8.94e-05	0.00102	CcSEcCtD
Bosutinib—Skin disorder—Mycophenolate mofetil—systemic scleroderma	8.9e-05	0.00101	CcSEcCtD
Bosutinib—Diarrhoea—Azathioprine—systemic scleroderma	8.81e-05	0.001	CcSEcCtD
Bosutinib—EPHB2—Diflorasone—Mometasone—systemic scleroderma	8.78e-05	0.0286	CbGdCrCtD
Bosutinib—Nausea—Captopril—systemic scleroderma	8.77e-05	0.000997	CcSEcCtD
Bosutinib—Abdominal discomfort—Methotrexate—systemic scleroderma	8.75e-05	0.000994	CcSEcCtD
Bosutinib—Asthenia—Leflunomide—systemic scleroderma	8.73e-05	0.000992	CcSEcCtD
Bosutinib—Pancytopenia—Methotrexate—systemic scleroderma	8.67e-05	0.000985	CcSEcCtD
Bosutinib—Feeling abnormal—Lisinopril—systemic scleroderma	8.61e-05	0.000979	CcSEcCtD
Bosutinib—Pruritus—Leflunomide—systemic scleroderma	8.61e-05	0.000978	CcSEcCtD
Bosutinib—Connective tissue disorder—Prednisone—systemic scleroderma	8.59e-05	0.000976	CcSEcCtD
Bosutinib—Gastrointestinal pain—Lisinopril—systemic scleroderma	8.55e-05	0.000972	CcSEcCtD
Bosutinib—Neutropenia—Methotrexate—systemic scleroderma	8.53e-05	0.00097	CcSEcCtD
Bosutinib—Dizziness—Azathioprine—systemic scleroderma	8.52e-05	0.000968	CcSEcCtD
Bosutinib—Upper respiratory tract infection—Methotrexate—systemic scleroderma	8.48e-05	0.000964	CcSEcCtD
Bosutinib—Musculoskeletal discomfort—Mycophenolate mofetil—systemic scleroderma	8.35e-05	0.000949	CcSEcCtD
Bosutinib—Asthenia—Mycophenolic acid—systemic scleroderma	8.33e-05	0.000947	CcSEcCtD
Bosutinib—Diarrhoea—Leflunomide—systemic scleroderma	8.32e-05	0.000946	CcSEcCtD
Bosutinib—Urticaria—Lisinopril—systemic scleroderma	8.3e-05	0.000944	CcSEcCtD
Bosutinib—Body temperature increased—Lisinopril—systemic scleroderma	8.26e-05	0.000939	CcSEcCtD
Bosutinib—Abdominal pain—Lisinopril—systemic scleroderma	8.26e-05	0.000939	CcSEcCtD
Bosutinib—Pruritus—Mycophenolic acid—systemic scleroderma	8.21e-05	0.000933	CcSEcCtD
Bosutinib—Vomiting—Azathioprine—systemic scleroderma	8.19e-05	0.000931	CcSEcCtD
Bosutinib—Pneumonia—Methotrexate—systemic scleroderma	8.18e-05	0.00093	CcSEcCtD
Bosutinib—Dyspnoea—Mycophenolate mofetil—systemic scleroderma	8.17e-05	0.000928	CcSEcCtD
Bosutinib—Infestation—Methotrexate—systemic scleroderma	8.14e-05	0.000925	CcSEcCtD
Bosutinib—Infestation NOS—Methotrexate—systemic scleroderma	8.14e-05	0.000925	CcSEcCtD
Bosutinib—Rash—Azathioprine—systemic scleroderma	8.12e-05	0.000923	CcSEcCtD
Bosutinib—Dermatitis—Azathioprine—systemic scleroderma	8.12e-05	0.000922	CcSEcCtD
Bosutinib—Headache—Azathioprine—systemic scleroderma	8.07e-05	0.000917	CcSEcCtD
Bosutinib—Dizziness—Leflunomide—systemic scleroderma	8.05e-05	0.000914	CcSEcCtD
Bosutinib—Renal failure—Methotrexate—systemic scleroderma	8e-05	0.000909	CcSEcCtD
Bosutinib—Decreased appetite—Mycophenolate mofetil—systemic scleroderma	7.96e-05	0.000905	CcSEcCtD
Bosutinib—Diarrhoea—Mycophenolic acid—systemic scleroderma	7.94e-05	0.000903	CcSEcCtD
Bosutinib—Gastrointestinal disorder—Mycophenolate mofetil—systemic scleroderma	7.91e-05	0.000899	CcSEcCtD
Bosutinib—Immune system disorder—Prednisone—systemic scleroderma	7.89e-05	0.000897	CcSEcCtD
Bosutinib—Pain—Mycophenolate mofetil—systemic scleroderma	7.83e-05	0.00089	CcSEcCtD
Bosutinib—Vomiting—Leflunomide—systemic scleroderma	7.74e-05	0.000879	CcSEcCtD
Bosutinib—Hepatobiliary disease—Methotrexate—systemic scleroderma	7.69e-05	0.000875	CcSEcCtD
Bosutinib—Dizziness—Mycophenolic acid—systemic scleroderma	7.68e-05	0.000872	CcSEcCtD
Bosutinib—Rash—Leflunomide—systemic scleroderma	7.67e-05	0.000872	CcSEcCtD
Bosutinib—Dermatitis—Leflunomide—systemic scleroderma	7.66e-05	0.000871	CcSEcCtD
Bosutinib—Nausea—Azathioprine—systemic scleroderma	7.65e-05	0.00087	CcSEcCtD
Bosutinib—Headache—Leflunomide—systemic scleroderma	7.62e-05	0.000866	CcSEcCtD
Bosutinib—Malnutrition—Prednisone—systemic scleroderma	7.61e-05	0.000865	CcSEcCtD
Bosutinib—Agranulocytosis—Methotrexate—systemic scleroderma	7.59e-05	0.000863	CcSEcCtD
Bosutinib—Feeling abnormal—Mycophenolate mofetil—systemic scleroderma	7.55e-05	0.000858	CcSEcCtD
Bosutinib—Asthenia—Lisinopril—systemic scleroderma	7.5e-05	0.000853	CcSEcCtD
Bosutinib—Gastrointestinal pain—Mycophenolate mofetil—systemic scleroderma	7.49e-05	0.000851	CcSEcCtD
Bosutinib—Pruritus—Lisinopril—systemic scleroderma	7.4e-05	0.000841	CcSEcCtD
Bosutinib—Vomiting—Mycophenolic acid—systemic scleroderma	7.38e-05	0.000839	CcSEcCtD
Bosutinib—Rash—Mycophenolic acid—systemic scleroderma	7.32e-05	0.000832	CcSEcCtD
Bosutinib—Dermatitis—Mycophenolic acid—systemic scleroderma	7.31e-05	0.000831	CcSEcCtD
Bosutinib—Hepatitis—Methotrexate—systemic scleroderma	7.3e-05	0.00083	CcSEcCtD
Bosutinib—Urticaria—Mycophenolate mofetil—systemic scleroderma	7.28e-05	0.000827	CcSEcCtD
Bosutinib—Headache—Mycophenolic acid—systemic scleroderma	7.27e-05	0.000826	CcSEcCtD
Bosutinib—Body temperature increased—Mycophenolate mofetil—systemic scleroderma	7.24e-05	0.000823	CcSEcCtD
Bosutinib—Abdominal pain—Mycophenolate mofetil—systemic scleroderma	7.24e-05	0.000823	CcSEcCtD
Bosutinib—Nausea—Leflunomide—systemic scleroderma	7.23e-05	0.000821	CcSEcCtD
Bosutinib—Urinary tract disorder—Methotrexate—systemic scleroderma	7.21e-05	0.00082	CcSEcCtD
Bosutinib—Urethral disorder—Methotrexate—systemic scleroderma	7.16e-05	0.000814	CcSEcCtD
Bosutinib—Diarrhoea—Lisinopril—systemic scleroderma	7.15e-05	0.000813	CcSEcCtD
Bosutinib—Ill-defined disorder—Prednisone—systemic scleroderma	7.06e-05	0.000802	CcSEcCtD
Bosutinib—Anaemia—Prednisone—systemic scleroderma	7.03e-05	0.000799	CcSEcCtD
Bosutinib—Dizziness—Lisinopril—systemic scleroderma	6.91e-05	0.000786	CcSEcCtD
Bosutinib—Erythema multiforme—Methotrexate—systemic scleroderma	6.91e-05	0.000785	CcSEcCtD
Bosutinib—Nausea—Mycophenolic acid—systemic scleroderma	6.89e-05	0.000784	CcSEcCtD
Bosutinib—Malaise—Prednisone—systemic scleroderma	6.86e-05	0.00078	CcSEcCtD
Bosutinib—Tinnitus—Methotrexate—systemic scleroderma	6.81e-05	0.000774	CcSEcCtD
Bosutinib—Cardiac disorder—Methotrexate—systemic scleroderma	6.78e-05	0.00077	CcSEcCtD
Bosutinib—Vomiting—Lisinopril—systemic scleroderma	6.65e-05	0.000756	CcSEcCtD
Bosutinib—Immune system disorder—Methotrexate—systemic scleroderma	6.6e-05	0.00075	CcSEcCtD
Bosutinib—Rash—Lisinopril—systemic scleroderma	6.59e-05	0.000749	CcSEcCtD
Bosutinib—Dermatitis—Lisinopril—systemic scleroderma	6.59e-05	0.000749	CcSEcCtD
Bosutinib—Mediastinal disorder—Methotrexate—systemic scleroderma	6.58e-05	0.000748	CcSEcCtD
Bosutinib—Asthenia—Mycophenolate mofetil—systemic scleroderma	6.57e-05	0.000747	CcSEcCtD
Bosutinib—Headache—Lisinopril—systemic scleroderma	6.55e-05	0.000744	CcSEcCtD
Bosutinib—Pruritus—Mycophenolate mofetil—systemic scleroderma	6.48e-05	0.000737	CcSEcCtD
Bosutinib—Arthralgia—Prednisone—systemic scleroderma	6.48e-05	0.000736	CcSEcCtD
Bosutinib—Myalgia—Prednisone—systemic scleroderma	6.48e-05	0.000736	CcSEcCtD
Bosutinib—Unspecified disorder of skin and subcutaneous tissue—Prednisone—systemic scleroderma	6.43e-05	0.000731	CcSEcCtD
Bosutinib—Discomfort—Prednisone—systemic scleroderma	6.4e-05	0.000727	CcSEcCtD
Bosutinib—Malnutrition—Methotrexate—systemic scleroderma	6.36e-05	0.000723	CcSEcCtD
Bosutinib—Diarrhoea—Mycophenolate mofetil—systemic scleroderma	6.27e-05	0.000712	CcSEcCtD
Bosutinib—Dysgeusia—Methotrexate—systemic scleroderma	6.23e-05	0.000708	CcSEcCtD
Bosutinib—Nausea—Lisinopril—systemic scleroderma	6.21e-05	0.000706	CcSEcCtD
Bosutinib—Anaphylactic shock—Prednisone—systemic scleroderma	6.21e-05	0.000706	CcSEcCtD
Bosutinib—Oedema—Prednisone—systemic scleroderma	6.21e-05	0.000706	CcSEcCtD
Bosutinib—Infection—Prednisone—systemic scleroderma	6.17e-05	0.000701	CcSEcCtD
Bosutinib—Back pain—Methotrexate—systemic scleroderma	6.15e-05	0.000699	CcSEcCtD
Bosutinib—Nervous system disorder—Prednisone—systemic scleroderma	6.09e-05	0.000692	CcSEcCtD
Bosutinib—Dizziness—Mycophenolate mofetil—systemic scleroderma	6.06e-05	0.000688	CcSEcCtD
Bosutinib—Skin disorder—Prednisone—systemic scleroderma	6.03e-05	0.000685	CcSEcCtD
Bosutinib—Ill-defined disorder—Methotrexate—systemic scleroderma	5.9e-05	0.000671	CcSEcCtD
Bosutinib—Anaemia—Methotrexate—systemic scleroderma	5.88e-05	0.000668	CcSEcCtD
Bosutinib—Vomiting—Mycophenolate mofetil—systemic scleroderma	5.82e-05	0.000662	CcSEcCtD
Bosutinib—Rash—Mycophenolate mofetil—systemic scleroderma	5.78e-05	0.000656	CcSEcCtD
Bosutinib—Dermatitis—Mycophenolate mofetil—systemic scleroderma	5.77e-05	0.000656	CcSEcCtD
Bosutinib—Headache—Mycophenolate mofetil—systemic scleroderma	5.74e-05	0.000652	CcSEcCtD
Bosutinib—Malaise—Methotrexate—systemic scleroderma	5.73e-05	0.000652	CcSEcCtD
Bosutinib—Leukopenia—Methotrexate—systemic scleroderma	5.69e-05	0.000647	CcSEcCtD
Bosutinib—Musculoskeletal discomfort—Prednisone—systemic scleroderma	5.66e-05	0.000643	CcSEcCtD
Bosutinib—Cough—Methotrexate—systemic scleroderma	5.55e-05	0.000631	CcSEcCtD
Bosutinib—Nausea—Mycophenolate mofetil—systemic scleroderma	5.44e-05	0.000618	CcSEcCtD
Bosutinib—Myalgia—Methotrexate—systemic scleroderma	5.41e-05	0.000615	CcSEcCtD
Bosutinib—Arthralgia—Methotrexate—systemic scleroderma	5.41e-05	0.000615	CcSEcCtD
Bosutinib—Chest pain—Methotrexate—systemic scleroderma	5.41e-05	0.000615	CcSEcCtD
Bosutinib—Decreased appetite—Prednisone—systemic scleroderma	5.4e-05	0.000613	CcSEcCtD
Bosutinib—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—systemic scleroderma	5.38e-05	0.000611	CcSEcCtD
Bosutinib—Fatigue—Prednisone—systemic scleroderma	5.35e-05	0.000608	CcSEcCtD
Bosutinib—Discomfort—Methotrexate—systemic scleroderma	5.35e-05	0.000608	CcSEcCtD
Bosutinib—Anaphylactic shock—Methotrexate—systemic scleroderma	5.19e-05	0.00059	CcSEcCtD
Bosutinib—Infection—Methotrexate—systemic scleroderma	5.16e-05	0.000586	CcSEcCtD
Bosutinib—Feeling abnormal—Prednisone—systemic scleroderma	5.12e-05	0.000582	CcSEcCtD
Bosutinib—Nervous system disorder—Methotrexate—systemic scleroderma	5.09e-05	0.000578	CcSEcCtD
Bosutinib—Thrombocytopenia—Methotrexate—systemic scleroderma	5.08e-05	0.000577	CcSEcCtD
Bosutinib—Gastrointestinal pain—Prednisone—systemic scleroderma	5.08e-05	0.000577	CcSEcCtD
Bosutinib—Skin disorder—Methotrexate—systemic scleroderma	5.04e-05	0.000573	CcSEcCtD
Bosutinib—Urticaria—Prednisone—systemic scleroderma	4.93e-05	0.000561	CcSEcCtD
Bosutinib—Body temperature increased—Prednisone—systemic scleroderma	4.91e-05	0.000558	CcSEcCtD
Bosutinib—Abdominal pain—Prednisone—systemic scleroderma	4.91e-05	0.000558	CcSEcCtD
Bosutinib—CYP3A4—digestive system—systemic scleroderma	4.81e-05	0.000616	CbGeAlD
Bosutinib—EPHB2—Diflorasone—Prednisone—systemic scleroderma	4.78e-05	0.0156	CbGdCrCtD
Bosutinib—Musculoskeletal discomfort—Methotrexate—systemic scleroderma	4.73e-05	0.000537	CcSEcCtD
Bosutinib—Dyspnoea—Methotrexate—systemic scleroderma	4.63e-05	0.000526	CcSEcCtD
Bosutinib—Decreased appetite—Methotrexate—systemic scleroderma	4.51e-05	0.000513	CcSEcCtD
Bosutinib—Gastrointestinal disorder—Methotrexate—systemic scleroderma	4.48e-05	0.000509	CcSEcCtD
Bosutinib—Fatigue—Methotrexate—systemic scleroderma	4.47e-05	0.000509	CcSEcCtD
Bosutinib—Asthenia—Prednisone—systemic scleroderma	4.45e-05	0.000506	CcSEcCtD
Bosutinib—Pain—Methotrexate—systemic scleroderma	4.44e-05	0.000504	CcSEcCtD
Bosutinib—Pruritus—Prednisone—systemic scleroderma	4.39e-05	0.000499	CcSEcCtD
Bosutinib—Feeling abnormal—Methotrexate—systemic scleroderma	4.28e-05	0.000486	CcSEcCtD
Bosutinib—Diarrhoea—Prednisone—systemic scleroderma	4.25e-05	0.000483	CcSEcCtD
Bosutinib—Gastrointestinal pain—Methotrexate—systemic scleroderma	4.24e-05	0.000482	CcSEcCtD
Bosutinib—Urticaria—Methotrexate—systemic scleroderma	4.12e-05	0.000469	CcSEcCtD
Bosutinib—Dizziness—Prednisone—systemic scleroderma	4.11e-05	0.000467	CcSEcCtD
Bosutinib—Abdominal pain—Methotrexate—systemic scleroderma	4.1e-05	0.000466	CcSEcCtD
Bosutinib—Body temperature increased—Methotrexate—systemic scleroderma	4.1e-05	0.000466	CcSEcCtD
Bosutinib—Vomiting—Prednisone—systemic scleroderma	3.95e-05	0.000449	CcSEcCtD
Bosutinib—Rash—Prednisone—systemic scleroderma	3.91e-05	0.000445	CcSEcCtD
Bosutinib—Dermatitis—Prednisone—systemic scleroderma	3.91e-05	0.000445	CcSEcCtD
Bosutinib—Headache—Prednisone—systemic scleroderma	3.89e-05	0.000442	CcSEcCtD
Bosutinib—Asthenia—Methotrexate—systemic scleroderma	3.72e-05	0.000423	CcSEcCtD
Bosutinib—Nausea—Prednisone—systemic scleroderma	3.69e-05	0.000419	CcSEcCtD
Bosutinib—Pruritus—Methotrexate—systemic scleroderma	3.67e-05	0.000417	CcSEcCtD
Bosutinib—Diarrhoea—Methotrexate—systemic scleroderma	3.55e-05	0.000404	CcSEcCtD
Bosutinib—Dizziness—Methotrexate—systemic scleroderma	3.43e-05	0.00039	CcSEcCtD
Bosutinib—ABCB1—digestive system—systemic scleroderma	3.4e-05	0.000436	CbGeAlD
Bosutinib—Vomiting—Methotrexate—systemic scleroderma	3.3e-05	0.000375	CcSEcCtD
Bosutinib—Rash—Methotrexate—systemic scleroderma	3.27e-05	0.000372	CcSEcCtD
Bosutinib—Dermatitis—Methotrexate—systemic scleroderma	3.27e-05	0.000372	CcSEcCtD
Bosutinib—Headache—Methotrexate—systemic scleroderma	3.25e-05	0.000369	CcSEcCtD
Bosutinib—Nausea—Methotrexate—systemic scleroderma	3.08e-05	0.00035	CcSEcCtD
Bosutinib—CSNK1E—Betamethasone—Mometasone—systemic scleroderma	3.03e-05	0.00988	CbGdCrCtD
Bosutinib—CSNK1E—Dexamethasone—Mometasone—systemic scleroderma	3.03e-05	0.00988	CbGdCrCtD
Bosutinib—ABCB1—lung—systemic scleroderma	2.84e-05	0.000364	CbGeAlD
Bosutinib—PKMYT1—Danazol—Prednisone—systemic scleroderma	2.72e-05	0.00884	CbGdCrCtD
Bosutinib—CSNK1E—Danazol—Prednisone—systemic scleroderma	2.59e-05	0.00844	CbGdCrCtD
Bosutinib—CSNK1E—Betamethasone—Prednisone—systemic scleroderma	1.65e-05	0.00538	CbGdCrCtD
Bosutinib—CSNK1E—Dexamethasone—Prednisone—systemic scleroderma	1.65e-05	0.00538	CbGdCrCtD
Bosutinib—CHEK2—Danazol—Prednisone—systemic scleroderma	1.33e-05	0.00432	CbGdCrCtD
Bosutinib—MAP2K1—Signaling Pathways—CSK—systemic scleroderma	4.14e-06	3.46e-05	CbGpPWpGaD
Bosutinib—CSNK1E—Disease—NOS3—systemic scleroderma	4.13e-06	3.45e-05	CbGpPWpGaD
Bosutinib—SRC—Immune System—BLK—systemic scleroderma	4.12e-06	3.45e-05	CbGpPWpGaD
Bosutinib—SRC—Disease—CD247—systemic scleroderma	4.11e-06	3.44e-05	CbGpPWpGaD
Bosutinib—BMPR2—Signaling Pathways—MMP9—systemic scleroderma	4.11e-06	3.43e-05	CbGpPWpGaD
Bosutinib—ERBB4—Signaling Pathways—EDN1—systemic scleroderma	4.1e-06	3.43e-05	CbGpPWpGaD
Bosutinib—SYK—Signaling Pathways—CCL2—systemic scleroderma	4.09e-06	3.42e-05	CbGpPWpGaD
Bosutinib—TBK1—Immune System—IL1B—systemic scleroderma	4.08e-06	3.41e-05	CbGpPWpGaD
Bosutinib—PTK2B—Signaling Pathways—EDN1—systemic scleroderma	4.04e-06	3.38e-05	CbGpPWpGaD
Bosutinib—PRKCQ—Signaling Pathways—CCL2—systemic scleroderma	4.02e-06	3.36e-05	CbGpPWpGaD
Bosutinib—CSNK1A1—Signaling Pathways—CCL2—systemic scleroderma	4.02e-06	3.36e-05	CbGpPWpGaD
Bosutinib—MAP2K2—Immune System—HLA-DQB1—systemic scleroderma	4.01e-06	3.35e-05	CbGpPWpGaD
Bosutinib—CAMK2G—Immune System—IL1B—systemic scleroderma	4.01e-06	3.35e-05	CbGpPWpGaD
Bosutinib—SRC—Platelet activation, signaling and aggregation—TGFB1—systemic scleroderma	3.96e-06	3.31e-05	CbGpPWpGaD
Bosutinib—EGFR—Immune System—CTLA4—systemic scleroderma	3.96e-06	3.31e-05	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—RHOB—systemic scleroderma	3.94e-06	3.3e-05	CbGpPWpGaD
Bosutinib—EGFR—Developmental Biology—MMP2—systemic scleroderma	3.94e-06	3.29e-05	CbGpPWpGaD
Bosutinib—BCR—Signaling Pathways—MMP9—systemic scleroderma	3.94e-06	3.29e-05	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling by GPCR—EDN1—systemic scleroderma	3.92e-06	3.28e-05	CbGpPWpGaD
Bosutinib—PDGFRB—Immune System—HLA-DQB1—systemic scleroderma	3.92e-06	3.27e-05	CbGpPWpGaD
Bosutinib—MAP3K3—Immune System—IL1B—systemic scleroderma	3.91e-06	3.27e-05	CbGpPWpGaD
Bosutinib—PTK2—Developmental Biology—TGFB1—systemic scleroderma	3.9e-06	3.26e-05	CbGpPWpGaD
Bosutinib—ROCK1—Signaling Pathways—EDN1—systemic scleroderma	3.9e-06	3.26e-05	CbGpPWpGaD
Bosutinib—CSK—Signaling Pathways—CCL2—systemic scleroderma	3.88e-06	3.24e-05	CbGpPWpGaD
Bosutinib—YES1—Developmental Biology—TGFB1—systemic scleroderma	3.85e-06	3.21e-05	CbGpPWpGaD
Bosutinib—LYN—Immune System—HLA-DQB1—systemic scleroderma	3.83e-06	3.2e-05	CbGpPWpGaD
Bosutinib—PTK2—Hemostasis—TGFB1—systemic scleroderma	3.83e-06	3.2e-05	CbGpPWpGaD
Bosutinib—LCK—Immune System—CTLA4—systemic scleroderma	3.82e-06	3.19e-05	CbGpPWpGaD
Bosutinib—ABL1—Immune System—HLA-DQB1—systemic scleroderma	3.82e-06	3.19e-05	CbGpPWpGaD
Bosutinib—MAP2K2—Immune System—IL1A—systemic scleroderma	3.81e-06	3.18e-05	CbGpPWpGaD
Bosutinib—BTK—Immune System—IL1B—systemic scleroderma	3.81e-06	3.18e-05	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—RHOB—systemic scleroderma	3.8e-06	3.18e-05	CbGpPWpGaD
Bosutinib—HCK—Disease—NOS3—systemic scleroderma	3.79e-06	3.17e-05	CbGpPWpGaD
Bosutinib—MAP2K2—Immune System—CD40LG—systemic scleroderma	3.79e-06	3.17e-05	CbGpPWpGaD
Bosutinib—FYN—Immune System—HLA-DQB1—systemic scleroderma	3.77e-06	3.15e-05	CbGpPWpGaD
Bosutinib—YES1—Hemostasis—TGFB1—systemic scleroderma	3.77e-06	3.15e-05	CbGpPWpGaD
Bosutinib—MAP2K1—Immune System—HLA-DQB1—systemic scleroderma	3.75e-06	3.14e-05	CbGpPWpGaD
Bosutinib—RPS6KB1—Signaling Pathways—EDN1—systemic scleroderma	3.75e-06	3.14e-05	CbGpPWpGaD
Bosutinib—MAP2K5—Signaling Pathways—EDN1—systemic scleroderma	3.75e-06	3.14e-05	CbGpPWpGaD
Bosutinib—FER—Signaling Pathways—TGFB1—systemic scleroderma	3.74e-06	3.13e-05	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—HSPG2—systemic scleroderma	3.72e-06	3.11e-05	CbGpPWpGaD
Bosutinib—PDGFRB—Immune System—IL1A—systemic scleroderma	3.72e-06	3.11e-05	CbGpPWpGaD
Bosutinib—PDGFRB—Immune System—CD40LG—systemic scleroderma	3.7e-06	3.09e-05	CbGpPWpGaD
Bosutinib—SYK—Signaling Pathways—NOS3—systemic scleroderma	3.65e-06	3.05e-05	CbGpPWpGaD
Bosutinib—MAP2K2—Developmental Biology—MMP9—systemic scleroderma	3.64e-06	3.04e-05	CbGpPWpGaD
Bosutinib—LYN—Immune System—IL1A—systemic scleroderma	3.64e-06	3.04e-05	CbGpPWpGaD
Bosutinib—IRAK4—Immune System—IL1B—systemic scleroderma	3.64e-06	3.04e-05	CbGpPWpGaD
Bosutinib—ABL1—Immune System—IL1A—systemic scleroderma	3.62e-06	3.03e-05	CbGpPWpGaD
Bosutinib—LYN—Immune System—CD40LG—systemic scleroderma	3.62e-06	3.03e-05	CbGpPWpGaD
Bosutinib—ERBB3—Signaling Pathways—EDN1—systemic scleroderma	3.62e-06	3.02e-05	CbGpPWpGaD
Bosutinib—ABL1—Immune System—CD40LG—systemic scleroderma	3.6e-06	3.01e-05	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—CSK—systemic scleroderma	3.59e-06	3e-05	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—HSPG2—systemic scleroderma	3.58e-06	3e-05	CbGpPWpGaD
Bosutinib—FYN—Immune System—IL1A—systemic scleroderma	3.58e-06	3e-05	CbGpPWpGaD
Bosutinib—PRKCQ—Signaling Pathways—NOS3—systemic scleroderma	3.58e-06	2.99e-05	CbGpPWpGaD
Bosutinib—CSNK1A1—Signaling Pathways—NOS3—systemic scleroderma	3.58e-06	2.99e-05	CbGpPWpGaD
Bosutinib—ERBB4—Disease—NOS3—systemic scleroderma	3.57e-06	2.98e-05	CbGpPWpGaD
Bosutinib—MAP2K1—Immune System—IL1A—systemic scleroderma	3.57e-06	2.98e-05	CbGpPWpGaD
Bosutinib—FYN—Immune System—CD40LG—systemic scleroderma	3.56e-06	2.98e-05	CbGpPWpGaD
Bosutinib—AXL—Signaling Pathways—TGFB1—systemic scleroderma	3.55e-06	2.97e-05	CbGpPWpGaD
Bosutinib—MAP2K1—Immune System—CD40LG—systemic scleroderma	3.54e-06	2.96e-05	CbGpPWpGaD
Bosutinib—SRC—Axon guidance—MMP9—systemic scleroderma	3.54e-06	2.96e-05	CbGpPWpGaD
Bosutinib—HCK—Immune System—IL1B—systemic scleroderma	3.49e-06	2.92e-05	CbGpPWpGaD
Bosutinib—LCK—Hemostasis—NOS3—systemic scleroderma	3.49e-06	2.91e-05	CbGpPWpGaD
Bosutinib—LYN—Developmental Biology—MMP9—systemic scleroderma	3.48e-06	2.91e-05	CbGpPWpGaD
Bosutinib—ABL1—Developmental Biology—MMP9—systemic scleroderma	3.46e-06	2.89e-05	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—CSK—systemic scleroderma	3.46e-06	2.89e-05	CbGpPWpGaD
Bosutinib—CSK—Signaling Pathways—NOS3—systemic scleroderma	3.46e-06	2.89e-05	CbGpPWpGaD
Bosutinib—FES—Signaling Pathways—MMP9—systemic scleroderma	3.44e-06	2.88e-05	CbGpPWpGaD
Bosutinib—FYN—Developmental Biology—MMP9—systemic scleroderma	3.43e-06	2.86e-05	CbGpPWpGaD
Bosutinib—EGFR—Signaling by GPCR—EDN1—systemic scleroderma	3.41e-06	2.85e-05	CbGpPWpGaD
Bosutinib—MAP2K1—Developmental Biology—MMP9—systemic scleroderma	3.41e-06	2.85e-05	CbGpPWpGaD
Bosutinib—BMPR2—Signaling Pathways—TGFB1—systemic scleroderma	3.39e-06	2.83e-05	CbGpPWpGaD
Bosutinib—CSNK1A1—Disease—TGFB1—systemic scleroderma	3.38e-06	2.83e-05	CbGpPWpGaD
Bosutinib—PRKCQ—Disease—TGFB1—systemic scleroderma	3.38e-06	2.83e-05	CbGpPWpGaD
Bosutinib—SRC—Immune System—CTLA4—systemic scleroderma	3.38e-06	2.82e-05	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—RHOB—systemic scleroderma	3.37e-06	2.81e-05	CbGpPWpGaD
Bosutinib—SRC—Developmental Biology—MMP2—systemic scleroderma	3.36e-06	2.81e-05	CbGpPWpGaD
Bosutinib—ERBB4—Immune System—IL1B—systemic scleroderma	3.29e-06	2.75e-05	CbGpPWpGaD
Bosutinib—CSK—Disease—TGFB1—systemic scleroderma	3.27e-06	2.73e-05	CbGpPWpGaD
Bosutinib—EGFR—Immune System—HLA-DQB1—systemic scleroderma	3.26e-06	2.72e-05	CbGpPWpGaD
Bosutinib—BCR—Signaling Pathways—TGFB1—systemic scleroderma	3.25e-06	2.71e-05	CbGpPWpGaD
Bosutinib—CSNK1E—Signaling Pathways—CCL2—systemic scleroderma	3.25e-06	2.71e-05	CbGpPWpGaD
Bosutinib—PTK2B—Immune System—IL1B—systemic scleroderma	3.24e-06	2.71e-05	CbGpPWpGaD
Bosutinib—PTK2—Signaling Pathways—EDN1—systemic scleroderma	3.22e-06	2.69e-05	CbGpPWpGaD
Bosutinib—YES1—Signaling Pathways—EDN1—systemic scleroderma	3.18e-06	2.65e-05	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—HSPG2—systemic scleroderma	3.17e-06	2.65e-05	CbGpPWpGaD
Bosutinib—BLK—Immune System—IL1B—systemic scleroderma	3.17e-06	2.65e-05	CbGpPWpGaD
Bosutinib—FGR—Immune System—IL1B—systemic scleroderma	3.15e-06	2.64e-05	CbGpPWpGaD
Bosutinib—ERBB3—Disease—NOS3—systemic scleroderma	3.15e-06	2.63e-05	CbGpPWpGaD
Bosutinib—LCK—Immune System—HLA-DQB1—systemic scleroderma	3.14e-06	2.63e-05	CbGpPWpGaD
Bosutinib—EGFR—Immune System—IL1A—systemic scleroderma	3.1e-06	2.59e-05	CbGpPWpGaD
Bosutinib—SRC—Hemostasis—NOS3—systemic scleroderma	3.09e-06	2.58e-05	CbGpPWpGaD
Bosutinib—EGFR—Immune System—CD40LG—systemic scleroderma	3.08e-06	2.57e-05	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—CSK—systemic scleroderma	3.06e-06	2.56e-05	CbGpPWpGaD
Bosutinib—IRAK1—Signaling Pathways—EDN1—systemic scleroderma	3.01e-06	2.52e-05	CbGpPWpGaD
Bosutinib—MAP2K2—Developmental Biology—TGFB1—systemic scleroderma	3e-06	2.51e-05	CbGpPWpGaD
Bosutinib—LCK—Immune System—IL1A—systemic scleroderma	2.98e-06	2.49e-05	CbGpPWpGaD
Bosutinib—LCK—Immune System—CD40LG—systemic scleroderma	2.97e-06	2.48e-05	CbGpPWpGaD
Bosutinib—EGFR—Developmental Biology—MMP9—systemic scleroderma	2.96e-06	2.47e-05	CbGpPWpGaD
Bosutinib—SYK—Signaling Pathways—MMP9—systemic scleroderma	2.93e-06	2.45e-05	CbGpPWpGaD
Bosutinib—ERBB3—Immune System—IL1B—systemic scleroderma	2.9e-06	2.42e-05	CbGpPWpGaD
Bosutinib—CSNK1E—Signaling Pathways—NOS3—systemic scleroderma	2.89e-06	2.42e-05	CbGpPWpGaD
Bosutinib—PRKCQ—Signaling Pathways—MMP9—systemic scleroderma	2.87e-06	2.4e-05	CbGpPWpGaD
Bosutinib—CSNK1A1—Signaling Pathways—MMP9—systemic scleroderma	2.87e-06	2.4e-05	CbGpPWpGaD
Bosutinib—LYN—Developmental Biology—TGFB1—systemic scleroderma	2.87e-06	2.4e-05	CbGpPWpGaD
Bosutinib—MAP2K2—Signaling by GPCR—CCL2—systemic scleroderma	2.87e-06	2.4e-05	CbGpPWpGaD
Bosutinib—ABL1—Developmental Biology—TGFB1—systemic scleroderma	2.86e-06	2.39e-05	CbGpPWpGaD
Bosutinib—FES—Signaling Pathways—TGFB1—systemic scleroderma	2.84e-06	2.37e-05	CbGpPWpGaD
Bosutinib—MAP3K7—Signaling Pathways—EDN1—systemic scleroderma	2.84e-06	2.37e-05	CbGpPWpGaD
Bosutinib—FYN—Developmental Biology—TGFB1—systemic scleroderma	2.82e-06	2.36e-05	CbGpPWpGaD
Bosutinib—LYN—Hemostasis—TGFB1—systemic scleroderma	2.81e-06	2.35e-05	CbGpPWpGaD
Bosutinib—MAP2K1—Developmental Biology—TGFB1—systemic scleroderma	2.81e-06	2.35e-05	CbGpPWpGaD
Bosutinib—ERBB4—Signaling Pathways—CCL2—systemic scleroderma	2.81e-06	2.34e-05	CbGpPWpGaD
Bosutinib—ABL1—Hemostasis—TGFB1—systemic scleroderma	2.8e-06	2.34e-05	CbGpPWpGaD
Bosutinib—SRC—Immune System—HLA-DQB1—systemic scleroderma	2.78e-06	2.32e-05	CbGpPWpGaD
Bosutinib—CSK—Signaling Pathways—MMP9—systemic scleroderma	2.77e-06	2.32e-05	CbGpPWpGaD
Bosutinib—FYN—Hemostasis—TGFB1—systemic scleroderma	2.77e-06	2.31e-05	CbGpPWpGaD
Bosutinib—PTK2B—Signaling Pathways—CCL2—systemic scleroderma	2.76e-06	2.31e-05	CbGpPWpGaD
Bosutinib—CSNK1E—Disease—TGFB1—systemic scleroderma	2.73e-06	2.28e-05	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling by GPCR—CCL2—systemic scleroderma	2.68e-06	2.24e-05	CbGpPWpGaD
Bosutinib—ROCK1—Signaling Pathways—CCL2—systemic scleroderma	2.66e-06	2.23e-05	CbGpPWpGaD
Bosutinib—SRC—Immune System—IL1A—systemic scleroderma	2.64e-06	2.21e-05	CbGpPWpGaD
Bosutinib—ABCB1—Integrated Pancreatic Cancer Pathway—TGFB1—systemic scleroderma	2.63e-06	2.2e-05	CbGpPWpGaD
Bosutinib—SRC—Immune System—CD40LG—systemic scleroderma	2.63e-06	2.2e-05	CbGpPWpGaD
Bosutinib—PTK2—Immune System—IL1B—systemic scleroderma	2.58e-06	2.16e-05	CbGpPWpGaD
Bosutinib—RPS6KB1—Signaling Pathways—CCL2—systemic scleroderma	2.57e-06	2.14e-05	CbGpPWpGaD
Bosutinib—MAP2K5—Signaling Pathways—CCL2—systemic scleroderma	2.57e-06	2.14e-05	CbGpPWpGaD
Bosutinib—YES1—Immune System—IL1B—systemic scleroderma	2.55e-06	2.13e-05	CbGpPWpGaD
Bosutinib—SRC—Developmental Biology—MMP9—systemic scleroderma	2.53e-06	2.11e-05	CbGpPWpGaD
Bosutinib—HCK—Disease—TGFB1—systemic scleroderma	2.51e-06	2.09e-05	CbGpPWpGaD
Bosutinib—ERBB4—Signaling Pathways—NOS3—systemic scleroderma	2.5e-06	2.09e-05	CbGpPWpGaD
Bosutinib—MAP2K2—Signaling Pathways—EDN1—systemic scleroderma	2.48e-06	2.07e-05	CbGpPWpGaD
Bosutinib—ERBB3—Signaling Pathways—CCL2—systemic scleroderma	2.47e-06	2.07e-05	CbGpPWpGaD
Bosutinib—PTK2B—Signaling Pathways—NOS3—systemic scleroderma	2.46e-06	2.06e-05	CbGpPWpGaD
Bosutinib—EGFR—Developmental Biology—TGFB1—systemic scleroderma	2.44e-06	2.04e-05	CbGpPWpGaD
Bosutinib—PDGFRB—Signaling Pathways—EDN1—systemic scleroderma	2.42e-06	2.02e-05	CbGpPWpGaD
Bosutinib—IRAK1—Immune System—IL1B—systemic scleroderma	2.42e-06	2.02e-05	CbGpPWpGaD
Bosutinib—SYK—Signaling Pathways—TGFB1—systemic scleroderma	2.41e-06	2.02e-05	CbGpPWpGaD
Bosutinib—ROCK1—Signaling Pathways—NOS3—systemic scleroderma	2.37e-06	1.98e-05	CbGpPWpGaD
Bosutinib—LYN—Signaling Pathways—EDN1—systemic scleroderma	2.37e-06	1.98e-05	CbGpPWpGaD
Bosutinib—CSNK1A1—Signaling Pathways—TGFB1—systemic scleroderma	2.37e-06	1.98e-05	CbGpPWpGaD
Bosutinib—PRKCQ—Signaling Pathways—TGFB1—systemic scleroderma	2.37e-06	1.98e-05	CbGpPWpGaD
Bosutinib—ERBB4—Disease—TGFB1—systemic scleroderma	2.36e-06	1.97e-05	CbGpPWpGaD
Bosutinib—FYN—Signaling Pathways—EDN1—systemic scleroderma	2.33e-06	1.95e-05	CbGpPWpGaD
Bosutinib—EGFR—Signaling by GPCR—CCL2—systemic scleroderma	2.33e-06	1.95e-05	CbGpPWpGaD
Bosutinib—CSNK1E—Signaling Pathways—MMP9—systemic scleroderma	2.32e-06	1.94e-05	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling Pathways—EDN1—systemic scleroderma	2.32e-06	1.94e-05	CbGpPWpGaD
Bosutinib—LCK—Hemostasis—TGFB1—systemic scleroderma	2.31e-06	1.93e-05	CbGpPWpGaD
Bosutinib—CSK—Signaling Pathways—TGFB1—systemic scleroderma	2.29e-06	1.91e-05	CbGpPWpGaD
Bosutinib—RPS6KB1—Signaling Pathways—NOS3—systemic scleroderma	2.29e-06	1.91e-05	CbGpPWpGaD
Bosutinib—MAP2K5—Signaling Pathways—NOS3—systemic scleroderma	2.29e-06	1.91e-05	CbGpPWpGaD
Bosutinib—MAP3K7—Immune System—IL1B—systemic scleroderma	2.27e-06	1.9e-05	CbGpPWpGaD
Bosutinib—ABCB1—Metabolism—HSPG2—systemic scleroderma	2.25e-06	1.88e-05	CbGpPWpGaD
Bosutinib—ERBB3—Signaling Pathways—NOS3—systemic scleroderma	2.2e-06	1.84e-05	CbGpPWpGaD
Bosutinib—PTK2—Signaling Pathways—CCL2—systemic scleroderma	2.2e-06	1.84e-05	CbGpPWpGaD
Bosutinib—YES1—Signaling Pathways—CCL2—systemic scleroderma	2.17e-06	1.81e-05	CbGpPWpGaD
Bosutinib—MAP2K2—Disease—NOS3—systemic scleroderma	2.16e-06	1.8e-05	CbGpPWpGaD
Bosutinib—PDGFRB—Disease—NOS3—systemic scleroderma	2.1e-06	1.76e-05	CbGpPWpGaD
Bosutinib—SRC—Developmental Biology—TGFB1—systemic scleroderma	2.08e-06	1.74e-05	CbGpPWpGaD
Bosutinib—ERBB3—Disease—TGFB1—systemic scleroderma	2.08e-06	1.74e-05	CbGpPWpGaD
Bosutinib—IRAK1—Signaling Pathways—CCL2—systemic scleroderma	2.06e-06	1.72e-05	CbGpPWpGaD
Bosutinib—SRC—Hemostasis—TGFB1—systemic scleroderma	2.04e-06	1.71e-05	CbGpPWpGaD
Bosutinib—FYN—Disease—NOS3—systemic scleroderma	2.03e-06	1.69e-05	CbGpPWpGaD
Bosutinib—MAP2K1—Disease—NOS3—systemic scleroderma	2.02e-06	1.69e-05	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—EDN1—systemic scleroderma	2.01e-06	1.68e-05	CbGpPWpGaD
Bosutinib—ERBB4—Signaling Pathways—MMP9—systemic scleroderma	2.01e-06	1.68e-05	CbGpPWpGaD
Bosutinib—MAP2K2—Immune System—IL1B—systemic scleroderma	1.99e-06	1.66e-05	CbGpPWpGaD
Bosutinib—PTK2B—Signaling Pathways—MMP9—systemic scleroderma	1.98e-06	1.65e-05	CbGpPWpGaD
Bosutinib—PTK2—Signaling Pathways—NOS3—systemic scleroderma	1.96e-06	1.64e-05	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—EDN1—systemic scleroderma	1.94e-06	1.62e-05	CbGpPWpGaD
Bosutinib—PDGFRB—Immune System—IL1B—systemic scleroderma	1.94e-06	1.62e-05	CbGpPWpGaD
Bosutinib—MAP3K7—Signaling Pathways—CCL2—systemic scleroderma	1.94e-06	1.62e-05	CbGpPWpGaD
Bosutinib—YES1—Signaling Pathways—NOS3—systemic scleroderma	1.93e-06	1.62e-05	CbGpPWpGaD
Bosutinib—CSNK1E—Signaling Pathways—TGFB1—systemic scleroderma	1.91e-06	1.6e-05	CbGpPWpGaD
Bosutinib—ROCK1—Signaling Pathways—MMP9—systemic scleroderma	1.9e-06	1.59e-05	CbGpPWpGaD
Bosutinib—LYN—Immune System—IL1B—systemic scleroderma	1.9e-06	1.59e-05	CbGpPWpGaD
Bosutinib—ABL1—Immune System—IL1B—systemic scleroderma	1.89e-06	1.58e-05	CbGpPWpGaD
Bosutinib—FYN—Immune System—IL1B—systemic scleroderma	1.87e-06	1.56e-05	CbGpPWpGaD
Bosutinib—MAP2K1—Immune System—IL1B—systemic scleroderma	1.86e-06	1.55e-05	CbGpPWpGaD
Bosutinib—IRAK1—Signaling Pathways—NOS3—systemic scleroderma	1.84e-06	1.53e-05	CbGpPWpGaD
Bosutinib—RPS6KB1—Signaling Pathways—MMP9—systemic scleroderma	1.83e-06	1.53e-05	CbGpPWpGaD
Bosutinib—MAP2K5—Signaling Pathways—MMP9—systemic scleroderma	1.83e-06	1.53e-05	CbGpPWpGaD
Bosutinib—ERBB3—Signaling Pathways—MMP9—systemic scleroderma	1.77e-06	1.48e-05	CbGpPWpGaD
Bosutinib—EGFR—Disease—NOS3—systemic scleroderma	1.75e-06	1.46e-05	CbGpPWpGaD
Bosutinib—MAP3K7—Signaling Pathways—NOS3—systemic scleroderma	1.73e-06	1.44e-05	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—EDN1—systemic scleroderma	1.72e-06	1.44e-05	CbGpPWpGaD
Bosutinib—ABCB1—Metabolism—CTGF—systemic scleroderma	1.7e-06	1.42e-05	CbGpPWpGaD
Bosutinib—MAP2K2—Signaling Pathways—CCL2—systemic scleroderma	1.69e-06	1.42e-05	CbGpPWpGaD
Bosutinib—LCK—Disease—NOS3—systemic scleroderma	1.69e-06	1.41e-05	CbGpPWpGaD
Bosutinib—ERBB4—Signaling Pathways—TGFB1—systemic scleroderma	1.65e-06	1.38e-05	CbGpPWpGaD
Bosutinib—PDGFRB—Signaling Pathways—CCL2—systemic scleroderma	1.65e-06	1.38e-05	CbGpPWpGaD
Bosutinib—PTK2B—Signaling Pathways—TGFB1—systemic scleroderma	1.63e-06	1.36e-05	CbGpPWpGaD
Bosutinib—LYN—Signaling Pathways—CCL2—systemic scleroderma	1.62e-06	1.35e-05	CbGpPWpGaD
Bosutinib—EGFR—Immune System—IL1B—systemic scleroderma	1.61e-06	1.35e-05	CbGpPWpGaD
Bosutinib—FYN—Signaling Pathways—CCL2—systemic scleroderma	1.59e-06	1.33e-05	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling Pathways—CCL2—systemic scleroderma	1.58e-06	1.32e-05	CbGpPWpGaD
Bosutinib—PTK2—Signaling Pathways—MMP9—systemic scleroderma	1.57e-06	1.32e-05	CbGpPWpGaD
Bosutinib—ROCK1—Signaling Pathways—TGFB1—systemic scleroderma	1.57e-06	1.31e-05	CbGpPWpGaD
Bosutinib—LCK—Immune System—IL1B—systemic scleroderma	1.56e-06	1.3e-05	CbGpPWpGaD
Bosutinib—YES1—Signaling Pathways—MMP9—systemic scleroderma	1.55e-06	1.3e-05	CbGpPWpGaD
Bosutinib—RPS6KB1—Signaling Pathways—TGFB1—systemic scleroderma	1.51e-06	1.26e-05	CbGpPWpGaD
Bosutinib—MAP2K5—Signaling Pathways—TGFB1—systemic scleroderma	1.51e-06	1.26e-05	CbGpPWpGaD
Bosutinib—MAP2K2—Signaling Pathways—NOS3—systemic scleroderma	1.51e-06	1.26e-05	CbGpPWpGaD
Bosutinib—SRC—Disease—NOS3—systemic scleroderma	1.49e-06	1.25e-05	CbGpPWpGaD
Bosutinib—PDGFRB—Signaling Pathways—NOS3—systemic scleroderma	1.47e-06	1.23e-05	CbGpPWpGaD
Bosutinib—IRAK1—Signaling Pathways—MMP9—systemic scleroderma	1.47e-06	1.23e-05	CbGpPWpGaD
Bosutinib—ERBB3—Signaling Pathways—TGFB1—systemic scleroderma	1.46e-06	1.22e-05	CbGpPWpGaD
Bosutinib—LYN—Signaling Pathways—NOS3—systemic scleroderma	1.44e-06	1.21e-05	CbGpPWpGaD
Bosutinib—MAP2K2—Disease—TGFB1—systemic scleroderma	1.43e-06	1.19e-05	CbGpPWpGaD
Bosutinib—FYN—Signaling Pathways—NOS3—systemic scleroderma	1.42e-06	1.19e-05	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling Pathways—NOS3—systemic scleroderma	1.41e-06	1.18e-05	CbGpPWpGaD
Bosutinib—PDGFRB—Disease—TGFB1—systemic scleroderma	1.39e-06	1.16e-05	CbGpPWpGaD
Bosutinib—MAP3K7—Signaling Pathways—MMP9—systemic scleroderma	1.39e-06	1.16e-05	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—HSPG2—systemic scleroderma	1.38e-06	1.16e-05	CbGpPWpGaD
Bosutinib—SRC—Immune System—IL1B—systemic scleroderma	1.38e-06	1.15e-05	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—CCL2—systemic scleroderma	1.38e-06	1.15e-05	CbGpPWpGaD
Bosutinib—FYN—Disease—TGFB1—systemic scleroderma	1.34e-06	1.12e-05	CbGpPWpGaD
Bosutinib—MAP2K1—Disease—TGFB1—systemic scleroderma	1.33e-06	1.11e-05	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—CCL2—systemic scleroderma	1.33e-06	1.11e-05	CbGpPWpGaD
Bosutinib—PTK2—Signaling Pathways—TGFB1—systemic scleroderma	1.3e-06	1.08e-05	CbGpPWpGaD
Bosutinib—YES1—Signaling Pathways—TGFB1—systemic scleroderma	1.28e-06	1.07e-05	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—NOS3—systemic scleroderma	1.23e-06	1.03e-05	CbGpPWpGaD
Bosutinib—IRAK1—Signaling Pathways—TGFB1—systemic scleroderma	1.21e-06	1.01e-05	CbGpPWpGaD
Bosutinib—MAP2K2—Signaling Pathways—MMP9—systemic scleroderma	1.21e-06	1.01e-05	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—NOS3—systemic scleroderma	1.18e-06	9.88e-06	CbGpPWpGaD
Bosutinib—PDGFRB—Signaling Pathways—MMP9—systemic scleroderma	1.18e-06	9.88e-06	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—CCL2—systemic scleroderma	1.17e-06	9.81e-06	CbGpPWpGaD
Bosutinib—EGFR—Disease—TGFB1—systemic scleroderma	1.16e-06	9.68e-06	CbGpPWpGaD
Bosutinib—LYN—Signaling Pathways—MMP9—systemic scleroderma	1.16e-06	9.67e-06	CbGpPWpGaD
Bosutinib—MAP3K7—Signaling Pathways—TGFB1—systemic scleroderma	1.14e-06	9.55e-06	CbGpPWpGaD
Bosutinib—FYN—Signaling Pathways—MMP9—systemic scleroderma	1.14e-06	9.52e-06	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling Pathways—MMP9—systemic scleroderma	1.13e-06	9.47e-06	CbGpPWpGaD
Bosutinib—LCK—Disease—TGFB1—systemic scleroderma	1.12e-06	9.33e-06	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—CTGF—systemic scleroderma	1.05e-06	8.76e-06	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—NOS3—systemic scleroderma	1.05e-06	8.75e-06	CbGpPWpGaD
Bosutinib—MAP2K2—Signaling Pathways—TGFB1—systemic scleroderma	9.98e-07	8.34e-06	CbGpPWpGaD
Bosutinib—SRC—Disease—TGFB1—systemic scleroderma	9.89e-07	8.26e-06	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—MMP9—systemic scleroderma	9.84e-07	8.23e-06	CbGpPWpGaD
Bosutinib—PDGFRB—Signaling Pathways—TGFB1—systemic scleroderma	9.74e-07	8.14e-06	CbGpPWpGaD
Bosutinib—LYN—Signaling Pathways—TGFB1—systemic scleroderma	9.54e-07	7.97e-06	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—MMP9—systemic scleroderma	9.49e-07	7.93e-06	CbGpPWpGaD
Bosutinib—FYN—Signaling Pathways—TGFB1—systemic scleroderma	9.39e-07	7.85e-06	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling Pathways—TGFB1—systemic scleroderma	9.34e-07	7.81e-06	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—MMP9—systemic scleroderma	8.4e-07	7.02e-06	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—TGFB1—systemic scleroderma	8.11e-07	6.78e-06	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—TGFB1—systemic scleroderma	7.82e-07	6.53e-06	CbGpPWpGaD
Bosutinib—ABCB1—Metabolism—NOS3—systemic scleroderma	7.41e-07	6.19e-06	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—TGFB1—systemic scleroderma	6.92e-07	5.78e-06	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—NOS3—systemic scleroderma	4.56e-07	3.81e-06	CbGpPWpGaD
